Description
Selumetinib (INN), is a medication for the treatment of children, two years of age and older, with neurofibromatosis type I (NF-1), a genetic disorder of the nervous system causing tumors to grow on nerves. It is taken by mouth.
Selumetinib was approved for medical use in the United States in April 2020, and in the European Union in June 2021.[8] The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.